Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo

Journal of Interferon and Cytokine Research

Volumn 19, Issue 8, 1999, Pages 869-876

  Bosio, Erika ^a   Beilharz, Manfred W ^a   Watson, Mark W ^a   Lawson, Cassandra M ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS C; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SJOEGREN SYNDROME; VIRUS INFECTION; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; RECEPTORS, INTERFERON; TREATMENT OUTCOME;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HEPATITIS C VIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

EID: 0032817561     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313389     Document Type: Article

References (22)

1. HARIA, M., and BENFIELD, P. (1995). Interferon-a-2a: A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 50, 873-896.
2. MAISCH, B., HUFNAGEL, G., SCHONIAN, U., and, HENHSTENBERG, C. (1995). The european study of epidemiology and treatment of cardiac inflammatory disease. (ESETCID). Eur. Heart J. 16(Suppl. 0), 173-175.
3. GREENWAY, H. (1992). Cutaneous tumours: condyloma acuminatum, basal cell carcinoma, squamous cell carcinoma and melanoma. In: Interferon: Principles and Medical Applications. S. Baron. F.D. Coppenhaver, W.R. Fleishmann Jr., T.K, Hughes Jr., G.R. Klimpel, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.) Gal veston: University of Texas Medical Branch at Gal veston Press, pp. 519-532.
4. LUBLIN, F.D., WHITAKER. J.N., EIDELMAN, B.H., MILLER, A.E., ARNASON, B.G.W., and BURKS, J.S. (1996). Management of patients receiving Interferon beta-lb for multiple sclerosis. Neurology 46, 12-18.
5. BARON, S., TYRING, S.K., FLEISCHMANN, W.R., COPPENHAVER, D.H., NIESEL, D.W., KLIMPEL, G.R., STANTON, G.J., and HUGHES, T.K. (1991). The Interferons: Mechanisms of action and clinical applications. J. Am. Med. Assn. 266, 1375-1383.
6. PLATANIAS, L.C., and GOLOMB, H.M. (1993). Hairy cell leukaemia. Bailliere's Clin. Haematol. 6, 887-898.
7. BROAD, S.A., and KHAN, M. (1996). Oral administration of IFN-a is superior to subcutaneous administration of IFN-a in the suppression of chronic relapsing experimental autoimmune encephalitis. J. Autoimmun. 9, 11-20.
8. SCHAFER, T.W., LIEBERMAN, M., COHEN, M., and CAME, P.E. (1972). Interferon administration orally: protection of neonatal mice from lethal virus challenge. Science 176, 1326-1327.
9. MOORE, B.R., KRAKWOKA, S., CUMMINS, J.M., and ROBERTSON, J.T. (1996). Changes in airway inflammatory cell populations in standardbred racehorses after interferon-alpha administration. Vet. Immunol. Immunopathol. 49, 347-358.
10. CUMMINS, J.M., MOCK, R.E., SHIVE, B.W., KRAKOWKA, S., RICHARDS, A.B., and HUTCHESON, D.P. (1995). Oral treatment of transmissible gastroenteritis with natural human interferon alpha: A field study. Vet. Immunol. Immunolopathol. 45, 355-360.
11. CABAN, J., MOSSOR-OSTROWSKA, J., ZYRKOWSKABTEDA, T.. ZEJC, M., JANAS-SKULINA, U., CIESLA. A., CUMMINS, J.M., and GEORGIADES, J.A. (1993). Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges. Archivum Immunologiae et Therapiae Experimental 41, 229-235.
12. GEORGIADES, J.A. (1996). Natural human interferon α may act differently when given parenterally or orally to patients chronically infected with hepatitis B virus. Archivum Immunologiae et Therapiae Experimentalis 44, 11-22.
13. BROD, S.A., FOOTE, B., DARCAN, S., PAPOLLA, M., and NELSON, L. (1997). Oral IFN-a delays IDDM in NOD mice. J. Interferon Cytokine Res. 17 S2, S87.
14. TAKAYAMA, S., IWAKI. K., NISHIDA, Y., TANAKA, M., FUJII, M., OHASHI, K., IKEDA, M., and KURIMOTO, M. (1997). Effects of oral-mucosal IFN-a on antibody production in mice with induced tolerance. J. Interferon Cytokine Res. 17 S2, S62.
15. NAGAO, Y., YAMASHIRO, K., HARA, N., HORISAWA, Y., KATO, K., and VEMURA, A. (1997). Oral mucosal administration of murine IFN-a potentiates immune responses in mice. J. Interferon Cytokine Res. 17 S2, S19.
16. SATOH, Y., KASAMA, K., SATO, M., KUWABARA, M., YANA1, A., and MINAGAWA, T. (1997). Induction of tissue 2′5′AS and suppression of delayed type of asthma reaction by oral administration of IFN-b in guinea pig asthma model. J. Interferon Cytokine Res. 17 S2, S96.
17. BEILHARZ, M.W., McDONALD, W., WATSON, M.W., HENG, J., McGEACHIE, J., and LAWSON, C.M. (1997). Low dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J Interferon Cytokine Res. 17, 625-630.
18. HUDSON, J.B. (1979). The murine cytomegalovirus as a model for the study of viral pathogenesis and persistant infections. Arch. Virol. 62, 1-29.
19. LAWSON, C.M., GRUNDY, J.E., and SHELLAM, G.R. (1988). Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice. J Gen. Virol. 69, 1987-1998.
20. PFEFFER, L.M., and DONNER, D.B. (1990). The down-regulation of a-interferon receptors in human lyphoblastiod cells: Relation to cellular responsiveness to the antiproliferative action of ainterferon. Cancer Res. 50, 2654-2657.
21. STANTON, G.J., LLOYD, R.E., SARZOTTI, M., and BLALOCK, J.E. (1989). Protection of mice from semliki forest virus infection by lymphocytes treated with low levels of interferon. Mol. Biother. 1, 305-310.
22. TOUGH, D.F., BORROW. P., and SPRENT, J. (1996). Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272, 1947-1950.